Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.45 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15353584 | 0.84 | WNT3A (0.46) | LOXL2WNT3ANSD2CCNCCDK8 | |
| SCHEMBL6915992 | 0.80 | PDE3B (0.48) | PDE3BPDE3ACCNCCDK8AAK1 | |
| SCHEMBL24767287 | 0.79 | CCNC (0.37) | LOXL2WNT3ACCNCCDK8LOX | |
| SCHEMBL14802467 | 0.79 | WNT3A (0.53) | LOXL2WNT3AAAK1 | |
| SCHEMBL24767258 | 0.78 | WNT3A (0.54) | WNT3ANSD2AAK1MTOR | |
| SCHEMBL1912303 | 0.77 | DYRK1A (0.56) | WNT3ADYRK1A | |
| SCHEMBL668247 | 0.74 | — | — | |
| SCHEMBL153686 | 0.73 | EGLN2 (0.48) | PDE3BPDE3AMTOR | |
| Hydrochloric Acid SCHEMBL5083664 | 0.73 | LOXL2 (0.55) | LOXL2LOXLOXL3 | |
| SCHEMBL24767561 | 0.72 | AAK1 (0.48) | PDE3BPDE3ALOXL2WNT3ACCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2588453-B1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| WO-2012003189-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | IRM LLC (BM) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | PDE3B 2399/4885PDE3A 2858/4885LOXL2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.